NA Proactive news snapshot: CB2 Insights, Avalon GloboCare, AIM ImmunoTech, Capstone Turbine …

CB2 Insights (CSE:CBII) (OTCMKTS:CBIIF), the medical cannabis data group, revealed it had increased its market presence in the UK, saying it will license its technology to MyAccess Clinics (MAC) to manage their patient data. The latter operates multiple clinics in the UK and is focused on providing care for patients with unmet needs, which licensed medicines have failed to address.

Avalon GloboCare Corp (NASDAQ:AVCO) announced Thursday it has initiated its first-in-human Phase I clinical trial of its flagship AVA-001 therapy in China to treat relapsed/refractory B-cell malignancies, including B-cell lymphoblastic leukemia and non-Hodgkin’s Lymphoma. The clinical trial of AVA-001, which is a leverage individualized CAR (Chimeric Antigen Receptor) T-cell therapy candidate for immuno-oncology, is being conducted at the Hebei Yanda Lu Daopei Hospital and Beijing Lu Daopei Hospital in China, the world’s single largest CAR-T treatment network with over 600 patients. CAR-T cells are engineered to express a receptor that recognizes a specific cancer surface target to attack.

AIM ImmunoTech Inc (NYSEAmerican:AIM) announced Thursday that the US Department of Defense has granted a four-year, $6.42 million “Breakthrough Award” to the Roswell Park Comprehensive Cancer Center for a clinical study on a combination of therapies, including the company’s drug Ampligen, in patients with brain-metastatic breast cancer (BMBC). In a statement, the company said the funding is through the DoD’s breast cancer research program, which started the Breakthrough Awards to support research that has the potential to end breast cancer. The Phase II trial, slated to kick off in 2020, will be the first clinical study to assess the effectiveness of a three-pronged strategy combining distinct immunotherapy approaches:

Capstone Turbine Corporation (NASDAQ:CPST) continues to convert major oil and gas customers using its clean-energy microturbines to long-term service contracts. The company on Thursday announced that Cal Microturbine, its exclusive distributor for California, Idaho, Oregon, and Washington, has signed a Factory Protection Plan (FPP) long-term service contract covering 2 megawatts of its microturbines installed at a single location in California.

NexTech AR Solutions (CSE:NTAR) (OTCMKTS:NEXCF) is tapping the services of a Hollywood veteran to lead the augmented reality company’s foray into the entertainment business. The New York- and Toronto-based company has hired Dr Barry Sandrew to take on the chief operating officer and executive producer role of AR Studios, which produces immersive augmented reality (AR) content. Sandrew brings three decades worth of founding and leading visual effects production studios in Hollywood and has worked on 65 of the highest-grossing 3D feature films released over the past ten years.

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) announced Thursday that a human clinical diagnostics laboratory reported successful results from beta testing using the company’s genetic analyzers. Assurance Scientific Laboratories in Alabama said that it had processed numerous urine samples that contained pathogens and found good correlation between LexaGene’s assay and its own process. Human clinical diagnostics is the next milestone in Massachusetts-based LexaGene’s pathogen-screening technology, which is currently being commercialized for veterinary medicine as well as agricultural industries.

Weekend Unlimited Inc (CSE:POT) (OTCMKTS:WKULF), revealed Thursday that it is entering the hemp-derived CBD space with its WKND! Wellness product line, which will soon be available online and for retail sales in the United States. In a statement, the Vancouver-based lifestyle-focused cannabis company said it was in “final development” mode for its WKND! Wellness Line product line.

Millennial Lithium Corp (CVE:ML) (OTCQB:MLNLF) is making good progress at the Pastos Grandes project in Argentina and expects to start treating brine at its pilot plant in December this year to produce battery-grade lithium carbonate. In a wide-ranging update on Thursday, the company revealed current work at the site in Salta province, included ongoing liming and feeding of brine to pilot ponds, the building of the pilot plant and an additional long-term pumping well test.

The Green Organic Dutchman Holdings Ltd (TSE:TGOD) (OTCMKTS:TGODF) is hosting site visits for analysts this week at its facilities to show off the depth of its certified organic cannabis production. The company said in a statement Thursday that it expects to welcome 25 analysts from Canada and the US to its facilities in Hamilton, Ontario and Valleyfield, Quebec on Thursday and Friday.

XPhyto Therapeutics Corp (CSE:XPHY) is bringing in a global cannabis consultant to design its cannabis facility in Germany.  In a press release Thursday, the company announced a two-year European consulting deal with international cannabis expert Stephen Schroeder to commission what it’s calling “The Bunker,” a top-notch hydroponics and extraction facility.

Duos Technologies Group, Inc. (OTCMKTS:DUOT),  a provider of intelligent security analytical technology solutions, has announced that it will be exhibiting at the 59th Annual Railway Interchange 2019, which is being held on September 22-24 in Minneapolis. Scott Carns, Duos executive vice president and interim COO said: “Exhibiting at the RSSI conference is a tremendous opportunity for Duos to raise our profile within the rail community and get our solutions in front of relevant industry personnel who understand the value our technology holds.”

1933 Industries Inc (CSE:TGIF) (OTCMKTS:TGIFF) has signed a 12-month licensing agreement with PLUGplay, a manufacturer of magnetic cannabis vaporizer cartridges. Under the terms of the deal announced Thursday, 1933 subsidiary Alternative Medicine Association will manufacture distillate and vape pens under the PLUGplay brand to distribute in Nevada.

1933 Industries also said its board of directors has approved the issue of bonus shares to its chairman, Brayden Sutton, and its chief executive officer, Christopher Rebentisch, under their respective employment contracts. The group added that Sutton will receive 291,901 shares and Rebentisch will receive 175,913 shares, all of which will be issued at a deemed price of $0.365 per share. The company further announced that, under the amended terms of two consulting agreements, it will also be issuing 650,000 share purchase warrants, in lieu of cash consideration, entitling the holder to purchase one common share at a price of $0.37 exercisable in whole or in part until June 13, 2022. The group said the bonus shares and the warrants will be subject to a four month regulatory hold period.

Royal Nickel Corp (CSE:RNX) said the Toronto Stock Exchange has noted that the company will list an additional 45 million shares at the open on September 20, 2019, as well as 22.5 million warrants – trading under the symbol RNX.WT – after its recent public offering. As stated in its short form prospectus, dated September 17, 2019, the company is issuing  45 million units at 40 cents per unit under the offering which it expects to close before the open on September 20. Each unit will consist of one share and one-half warrant, with each whole warrant being exercisable at 50 cents per share until 5 pm Toronto time on the date that is 24 months following the closing date of the offering.

Medexus Pharmaceuticals Inc. (CVE:MDP) (OTCMKTS:PDDPF) announced that voting results from its Annual Meeting of Shareholders, held on September 18, 2019 in Toronto, saw each of its director nominees elected by a show of hands with over a 99% share. It added that each of the other matters put forward before shareholders for consideration and approval at the meeting, as described in the management information circular, was duly approved by the requisite number of votes.

Story by ProactiveInvestors